Abstract
Despite the advances in the pharmacological treatment with the introduction to the market of new biological agents, a significant proportion of patients with inflammatory bowel disease (IBD) still suffer an aggressive disease course. Moreover, surgery is not always a viable option due to the location or extent of the disease, particularly in complicated Crohn’s disease patients (e.g., in the presence of fistulas). Lately, stem cell (SC)-based therapy, mainly comprising hematopoietic SCs (HSCs) and mesenchymal SCs (MSCs), has been proposed as an alternative approach to biological agents for IBD treatment. The rapid advances that occurred in MSC research, known to exhibit regenerative, paracrine, and immunoregulatory properties, have raised hope for their therapeutic potential in IBD, especially after the recent official approval of darvadstrocel, the first allogeneic MSC therapy in Europe. In this chapter, the pathophysiology of gastrointestinal SCs and all the latest literature concerning their use in IBD treatment are discussed, mainly focusing on the latest clinical trials in IBD patients. Finally, safety of HSC- and MSC-based therapies are discussed, and insight is provided for the questions needed to be answered by future studies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424–9.
Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390:2769–78.
Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.e42.
Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterology. 2013;145:158–65.e2.
Fiocchi C. IBD: advances in pathogenesis, complications, diagnosis, and therapy. Curr Opin Gastroenterol. 2012;28:297–300.
Sandborn WJ. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 2008;135:1442–7.
Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut. 2011;60:788–98.
van Deen WK, Oikonomopoulos A, Hommes DW. Stem cell therapy in inflammatory bowel disease: which, when and how? Curr Opin Gastroenterol. 2013;29:384–90.
Lanzoni G, Roda G, Belluzzi A, et al. Inflammatory bowel disease: moving toward a stem cell-based therapy. World J Gastroenterol. 2008;14:4616–26.
Pilpilidis I, Kountouras J, Zavos C, Katsinelos P. Upper gastrointestinal carcinogenesis: H. pylori and stem cell cross-talk. J Surg Res. 2011;166:255–64.
Singh UP, Singh NP, Singh B, et al. Stem cells as potential therapeutic targets for inflammatory bowel disease. Front Biosci (Schol Ed). 2010;2:993–1008.
van der Flier LG, Clevers H. Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol. 2009;71:241–60.
Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007;25:2739–49.
Friedenstein AJ, Chailakhyan RK, Latsinik NV, et al. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation. 1974;17:331–40.
Wang M, Yuan Q, Xie L. Mesenchymal stem cell-based immunomodulation: properties and clinical application. Stem Cells Int. 2018;2018:3057624.
Brittan M, Alison MR, Schier S, Wright NA. Bone marrow stem cell-mediated regeneration in IBD: where do we go from here? Gastroenterology. 2007;132:1171–3.
Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J Phys. 1999;277:183–201.
Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol. 2014;15:1009–16.
Keating A. Mesenchymal stromal cells. Curr Opin Hematol. 2006;13:419–25.
Gordon JN, Pickard KM, Di Sabatino A, Prothero JD, Pender SL, Goggin PM, MacDonald TT. Matrix metalloproteinase-3 production by gut IgG plasma cells in chronic inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:195–203.
Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, Galun E, Rachmilewitz J. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood. 2005;105:2214–9.
Gratwohl A, Passweg J, Gerber I, Tyndall A. Stem cell transplantation for autoimmune diseases. Best Pract Res Clin Haematol. 2001;14:755–76.
Marmont AM. Stem cell transplantation for autoimmune disorders. Coincidental autoimmune disease in patients transplanted for conventional indications. Best Pract Res Clin Haematol. 2004;17:223–32.
Kountouras J, Sakellari I, Tsarouchas G, et al. Autologous haematopoietic stem cell transplantation in a patient with refractory Crohn’s disease. J Crohns Colitis. 2011;5:275–6.
Kriván G, Szabó D, Kállay K, et al. Successful autologous haematopoietic stem cell transplantation in severe, therapy-resistant childhood Crohn’s disease. Report on the first case in Hungary. Orv Hetil. 2014;155:789–92.
Ruiz MA, Kaiser Junior RL, de Quadros LG, et al. Hematopoietic stem cell transplantation in a severe refractory Crohn’s disease patient with intestinal stoma: a case report. Int Med Case Rep J. 2017;10:353–9.
Drakos PE, Nagler A, Or R. Case of Crohn’s disease in bone marrow transplantation. Am J Hematol. 1993;43:157–8.
Gratwohl A, Passweg J, Bocelli-Tyndall C, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant. 2005;35:869–79.
Oyama Y, Craig RM, Traynor AE, et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn’s disease. Gastroenterology. 2005;128:552–63.
Cassinotti A, Annaloro C, Ardizzone S, et al. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn’s disease. Gut. 2008;57:211–7.
Burt RK, Craig RM, Milanetti F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood. 2010;116:6123–32.
Hommes DW, Duijvestein M, Zelinkova Z, et al. Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn’s disease. J Crohns Colitis. 2011;5:543–9.
Snowden JA, Panés J, Alexander T, European Crohn’s and Colitis Organisation (ECCO), European Society for Blood and Marrow Transplantation (EBMT), Autoimmune Diseases Working Party (ADWP), Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE), et al. Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in severe crohn’s disease: a review on behalf of ECCO and EBMT. J Crohns Colitis. 2018;12:476–88.
López-García A, Rovira M, Jauregui-Amezaga A, et al. Autologous haematopoietic stem cell transplantation for refractory Crohn’s disease: efficacy in a single-centre cohort. J Crohns Colitis. 2017;11:1161–8.
Hawkey CJ, Allez M, Clark MM, et al. Autologous hematopoietic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA. 2015;314:2524–34.
Burt RK, Ruiz MA, Kaiser RL Jr. Stem cell transplantation for refractory Crohn disease. JAMA. 2016;315:2620.
Hawkey CJ, Lindsay J, Gribben J. Stem cell transplantation for refractory Crohn disease–reply. JAMA. 2016;315:2620–1.
Lindsay JO, Allez M, Clark M, ASTIC trial group, European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party, European Crohn’s and Colitis Organisation, et al. Autologous stem-cell transplantation in treatment-refractory Crohn’s disease: an analysis of pooled data from the ASTIC trial. Lancet Gastroenterol Hepatol. 2017;2:399–406.
Rabian F, Porcher R, Sicre de Fontbrune F, French Society of Bone Marrow Transplantation and Cell Therapy, et al. Influence of previous inflammatory bowel disease on the outcome of allogeneic hematopoietic stem cell transplantation: a matched-pair analysis. Biol Blood Marrow Transplant. 2016;22:1721–4.
Mayne CG, Williams CB. Induced and natural regulatory T cells in the development of inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:1772–88.
Stappenbeck TS, Miyoshi H. The role of stromal stem cells in tissues regeneration and wound repair. Science. 2009;324:1666–9.
Ditschkowski M, Einsele H, Schwerdtfeger R, et al. Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation. Transplantation. 2003;75:1745–7.
Tsuchiya A, Kojima Y, Ikarashi S, et al. Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases. Inflamm Regen. 2017;37:16.
Molendijk I, Bonsing BA, Roelofs H, et al. Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn’s disease. Gastroenterology. 2015;149:918–27.
Duijvestein M, Vos AC, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut. 2010;59:1662–9.
Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut. 2011;60:788–98.
Forbes GM, Sturm MJ, Leong RW, et al. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn’s disease refractory to biologic therapy. Clin Gastroenterol Hepatol. 2014;12:64–71.
Taupin P. OTI-010 Osiris Therapeutics/JCR pharmaceuticals. Curr Opin Investig Drugs. 2006;7:473–81.
Gazouli M, Roubelakis MG, Theodoropoulos GE. Stem cells as potential targeted therapy for inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:952–5.
Hu J, Zhao G, Zhang L, et al. Safety and therapeutic effect of mesenchymal stem cell infusion on moderate to severe ulcerative colitis. Exp Ther Med. 2016;12:2983–9.
Zhang J, Lv S, Liu X, Song B, Shi L. Umbilical cord mesenchymal stem cell treatment for Crohn’s disease: a randomized controlled clinical trial. Gut Liver. 2018;12:73–8.
Kim Y. Can umbilical cord mesenchymal stem cells treatment be a hope for patients with refractory Crohn’s disease? Gut Liver. 2018;12:5–6.
Mayer L, Pandak WM, Melmed GY, et al. Safety and tolerability of human placenta-derived cells (PDA001) in treatment-resistant Crohn’s disease: a phase 1 study. Inflamm Bowel Dis. 2013;19:754–60.
Zhang XM, Zhang YJ, Wang W, Wei YQ, Deng HX. Mesenchymal stem cells to treat Crohn’s disease with fistula. Hum Gene Ther. 2017;28:534–40.
García-Olmo D, García-Arranz M, Herreros D, et al. A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48:1416–23.
Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009;52:79–86.
Guadalajara H, Herreros D, De-La-Quintana P, Trebol J, Garcia-Arranz M, Garcia-Olmo D. Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. Int J Color Dis. 2012;27:595–600.
Cho YB, Lee WY, Park KJ, Kim M, Yoo HW, Yu CS. Autologous adipose tissue-derived stem cells for the treatment of Crohn’s fistula: a phase I clinical study. Cell Transplant. 2013;22:279–85.
Lee WY, Park KJ, Cho YB, et al. Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn’s fistula. Stem Cells. 2013;31:2575–81.
Cho YB, Park KJ, Yoon SN, et al. Long-term results of adipose-derived stem cell therapy for the treatment of Crohn’s fistula. Stem Cells Transl Med. 2015;4:532–7.
Wainstein C, Quera R, Kronberg U, et al. Mesenchymal stem cells and platelet-rich plasma in the treatment of patients with perineal Crohn’s disease. Int J Color Dis. 2016;31:725–6.
Wainstein C, Quera R, Fluxá D, et al. Stem cell therapy in refractory perineal crohn’s disease: long-term follow-up. Colorectal Dis. 2018 Jan 6. (in press).
Panes J, Garcia-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388:1281–90.
Press release. TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval to treat complex perianal fistulas in Crohn’s disease in Europe. 2018 Mar 23. Available at: http://tigenix.com/wp-content/uploads/2018/03/20180323-TiGenix-Takeda-EC-approval-PR-ENG-FINAL-clean.pdf.
Wei H, Liu X, Ouyang C, Zhang J, Chen S, Lu F, Chen L. Complications following stem cell therapy in inflammatory bowel disease. Curr Stem Cell Res Ther. 2017;12:471–5.
Røsland GV, Svendsen A, Torsvik A, et al. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Res. 2009;69:5331–9.
Bernardo ME, Zaffaroni N, Novara F, et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 2007;67:9142–9.
Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface Bone Marrow Transpl. 2009;44:453–5.
Jauregui-Amezaga A, Rovira M, Marín P, et al. Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn's disease. Gut. 2016;65:1456–62.
Conklin LS, Hanley PJ, Galipeau J, Barrett J, Bollard CM. Intravenous mesenchymal stromal cell therapy for inflammatory bowel disease: lessons from the acute graft versus host disease experience. Cytotherapy. 2017;19:655–67.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Zavos, C. (2019). Stem Cells in Inflammatory Bowel Disease: From Pathogenesis to Clinical Practice. In: Gazouli, M., Theodoropoulos, G. (eds) Digestive System Diseases. Stem Cell Biology and Regenerative Medicine. Humana Press, Cham. https://doi.org/10.1007/978-3-030-11965-2_8
Download citation
DOI: https://doi.org/10.1007/978-3-030-11965-2_8
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-030-11964-5
Online ISBN: 978-3-030-11965-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)